Reply to Araki et al

Eur J Cancer. 2013 Jun;49(9):2266-8. doi: 10.1016/j.ejca.2013.02.037. Epub 2013 Apr 8.

Authors

Allan Lipton¹, Karim Fizazi², Alison T Stopeck³, David H Henry⁴, Ada H Braun⁵

Affiliations

¹ Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: [email protected].
² Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
³ University of Arizona, Arizona Cancer Center, Tucson, AZ, USA.
⁴ Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA, USA.
⁵ Amgen Inc., Thousand Oaks, CA, USA.

PMID: 23578571
DOI: 10.1016/j.ejca.2013.02.037

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Bone Density Conservation Agents / therapeutic use*
Bone Neoplasms / drug therapy*
Bone Neoplasms / secondary*
Diphosphonates / therapeutic use*
Female
Humans
Imidazoles / therapeutic use*
Male

Substances

Antibodies, Monoclonal, Humanized
Bone Density Conservation Agents
Diphosphonates
Imidazoles